Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Report and Forecast 2024-2032

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Report and Forecast 2024-2032


Market Outlook

According to the report by Expert Market Research (EMR), the global selective serotonin reuptake inhibitors (SSRIs) market is projected to grow at a CAGR of 4.2% between 2024 and 2032. Aided by the growing prevalence of mental health disorders and the increasing awareness of the importance of mental health, the market is expected to grow significantly by 2032.

Selective Serotonin Reuptake Inhibitors, commonly known as SSRIs, are a class of drugs primarily prescribed as antidepressants in the treatment of major depressive disorders and anxiety conditions. SSRIs work by increasing levels of serotonin in the brain. Serotonin is a neurotransmitter that contributes to a person's happiness and well-being. SSRIs are known for their efficacy, relatively low side effects, and safety, making them a preferred choice for treating depression and other related disorders. It is extensively utilised in the healthcare sector which is leading to a heightened selective serotonin reuptake inhibitors (SSRIs) market growth.

The growing prevalence of mental health disorders, such as depression and anxiety, has been a significant factor propelling the demand for SSRIs. The increasingly stressful lives, marked by a fast-paced modern lifestyle and the myriad challenges posed by socio-economic factors, have contributed to a rise in mental health issues globally. The selective serotonin reuptake inhibitors (SSRIs) market demand is getting bolstered by the increasing health awareness of the population.

Furthermore, with the diminishing stigma around mental health issues and growing awareness, more individuals are seeking professional help and are thus being prescribed medications like SSRIs, which are often a first line of treatment for anxiety and depressive disorders.

Pharmaceutical research and development are undergoing a transformative phase, with a focus on developing new molecules with higher efficacy and fewer side effects. This movement is not lost on SSRIs. Advances in genetic testing are beginning to enable more personalised approaches to prescribing SSRIs. By considering a patient's unique genetic makeup, clinicians can predict with greater accuracy which SSRIs will be most effective and carry the least risk of side effects for each patient, thereby reducing the often-lengthy trial-and-error process to find the most effective medication.

Originally developed to treat depression, SSRIs have found utility in various other conditions, significantly broadening the selective serotonin reuptake inhibitors (SSRIs) market outlook. They are now routinely used to treat various anxiety disorders, including generalised anxiety disorder, panic disorder, and social anxiety disorder, as well as other conditions such as obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD).

This expansion of indications is a crucial factor contributing to the sustained growth of the SSRIs market.

Market Segmentation

The market can be divided based on application and region.

Market Breakup by Application
  • Depression
  • Anxiety and Panic Disorder
  • Other Mental Conditions
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global selective serotonin reuptake inhibitors (SSRIs) market. Some of the major players explored in the report by Expert Market Research are as follows:
  • Allergan plc
  • Eli Lilly and Company
  • Pfizer Inc.
  • H. Lundbeck A/S
  • Others
About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis
8.1 Key Industry Highlights
8.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market (2018-2023)
8.3 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast (2024-2032)
8.4 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Application
8.4.1 Depression
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Anxiety and Panic Disorder
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Other Mental Conditions
8.5 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Region
8.5.1 North America
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Europe
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Asia Pacific
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Latin America
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Middle East and Africa
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
9 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Allergan plc
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Eli Lilly and Company
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Pfizer Inc.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 H. Lundbeck A/S
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Key Industry Highlights, 2018 and 2032
2. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Application (USD Million), 2018-2023
3. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Application (USD Million), 2024-2032
4. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Region (USD Million), 2018-2023
5. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Region (USD Million), 2024-2032
6. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Country (USD Million), 2018-2023
7. North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Country (USD Million), 2024-2032
8. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Country (USD Million), 2018-2023
9. Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Country (USD Million), 2018-2023
11. Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Country (USD Million), 2018-2023
13. Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Middle East and Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Historical Market: Breakup by Country (USD Million), 2018-2023
15. Middle East and Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Structure

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings